


Atty. Docket No: EX98-001

Applicant: Luo and Xu  
Serial No.: 09/041,236  
Filed: March 11, 1998  
For: *Semaphorin K1*  
Group: 1643  
Examiner: N/A



**POWER OF ATTORNEY BY ASSIGNEE UNDER 37 CFR 3.71  
AND  
CERTIFICATE UNDER 37 CFR 3.73(b)**

The undersigned assignee of the entire interest in the above-identified subject patent application hereby appoints Richard Aron Osman, Ph.D., Reg No 36,627, as its attorney to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 CFR 3.71.

[ ] I hereby revoke all previous powers of attorney or authorizations of agents in the above identified application.

Please direct all correspondence to:  
Richard Aron Osman, Ph.D.  
SCIENCE & TECHNOLOGY LAW GROUP  
75 Denise Drive  
Hillsborough, CA 94010  
Tel: 650-343-4341

Applicant: Yuling Luo and Xiaomei Xu

Application No.: 09/041,236 Filed: March 11, 1998

Entitled: Semaphorin K1

Exelixis Pharmaceuticals, Inc.

(Name of Assignee)

, a Corporation

(Type of Assignee, e.g., corporation, university, government agency etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel\_\_\_\_\_, Frame\_\_\_\_\_, or for which a copy thereof is attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of the undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application nor any patent issuing thereon.

May 11, 1998  
Date

Exelixis Pharmaceuticals, Inc.

George Scangos  
George Scangos, President and C.E.O.  
260 Littlefield Avenue  
South San Francisco, CA 94080

## DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **Semaphorin K1** the specification of which having US Serial No. 09/041,236 filed on March 11, 1998.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

Address all correspondence to: Richard Aron Osman, Ph.D., Science & Technology Law Group, 75 Denise Drive, Hillsborough, CA 94010, Telephone: (650) 343-4341 Fax: (650) 343-4342

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor:

Yuling Luo

Inventor's signature:

Date:

Residence (city/state):

Citizenship:

Post Office Address:

5/8/98

South San Francisco, CA

China

Exelixis Pharmaceuticals, Inc., 260 Littlefield Ave  
South San Francisco, CA 94080

Inventor:

Xiaomei Xu

Inventor's signature:

Date:

Residence (city/state):

Citizenship:

Post Office Address:


5/8/98

South San Francisco, CA

China

Exelixis Pharmaceuticals, Inc., 260 Littlefield Ave  
South San Francisco, CA 94080

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**



I hereby declare that I am ☐ the owner of the small business concern identified below or ☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN: Exelixis Pharmaceuticals, Inc.

ADDRESS OF SMALL BUSINESS CONCERN: 260 Littlefield Ave., South San Francisco, CA 94080

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled *Semaphorin K1*, and having the named inventor(s) Yuling Luo and Xiaomei Xu described in Application Serial No. 09/041,236 filed March 11, 1998. If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). \*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Name: \_\_\_\_\_

Address: \_\_\_\_\_

☐ Individual      ☐ Small Business Concern      ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name/Title: George Scangos, President and C.E.O.

Address: Exelixis Pharmaceuticals, Inc., 260 Littlefield Ave., South San Francisco, CA 94080

SIGNATURE

DATE

May 13, 1998